Anastrozole
About
Therapy type: Hormone therapy
Therapy strategy: Aromatase inhibition
Mappings
NCI Thesaurus: Anastrozole (ncit:C1607)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | ER positive, HER2-negative | Invasive Breast Carcinoma | Abemaciclib, Anastrozole | |
| FDA (2) | HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Anastrozole | |
| FDA (2) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Anastrozole | |
| FDA (1) HC (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Anastrozole, Ribociclib | |
| FDA (1) HC (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Ribociclib | |
| FDA (1) HC (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Ribociclib | |
| FDA (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| FDA (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| FDA (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib |